|
1
|
Linn YC and Hui KM: Cytokine-induced
NK-like T cells: from bench to bedside. J Biomed Biotechnol.
2010:4357452010.PubMed/NCBI
|
|
2
|
Yamazaki H, Shiomi H, Tsubokura T, Kodani
N, Nishimura T, Aibe N, Udono H, Nishikata M, Baba Y, Ogita M,
Yamashita K and Kotsuma T: Quantitative assessment of
inter-observer variability in target volume delineation on
stereotactic radiotherapy treatment for pituitary adenoma and
meningioma near optic tract. Radiat Oncol. 6:102011.
|
|
3
|
Wang YS, Wang YY, Jiang P, Ma JJ, Qu Z,
Wang XL, Li JT and Jia XF: Short-term outcomes of CyberKnife
therapy for advanced high-risk tumors: A report of 160 cases. Exp
Ther Med. 3:725–727. 2012.PubMed/NCBI
|
|
4
|
Wang CC, Floyd SR, Chang CH, Warnke PC,
Chio CC, Kasper EM, Mahadevan A, Wong ET and Chen CC: Cyberknife
hypofractionated stereotactic radiosurgery (HSRS) of resection
cavity after excision of large cerebral metastasis: efficacy and
safety of an 800 cGy × 3 daily fractions regimen. J Neurooncol.
106:601–610. 2012.PubMed/NCBI
|
|
5
|
Verneris MR, Baker J, Edinger M and Negrin
RS: Studies of ex vivo activated and expanded CD8+NK-T
cells in humans and mice. J Clin Immunol. 22:131–136. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume
KG and Weissmen IL: Use of a SCID mouse/human lymphoma model to
evaluate cytokine-induced killer cells with potent antitumor cell
activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar
|
|
7
|
Schmidt-Wolf GD, Negrin RS and
Schmidt-Wolf IG: Activated T cells and cytokine-induced
CD3+CD56+killer cells. Ann Hematol. 74:51–56.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmidt-Wolf IG, Lefterova P, Mehta BA,
Fernandez LP, Huhn D, Blume KG, Weissman IL and Negrin RS:
Phenotypic characterization and identification of effector cells
involved in tumor cell recognition of cytokine-induced killer
cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
|
|
9
|
Nishimura R, Baker J, Beilhack A, Zeiser
R, Olson JA, Sega EI, Karimi M and Negrin RS: In vivo trafficking
and survival of cytokine-induced killer cells resulting in minimal
GVHD with retention of antitumor activity. Blood. 112:2563–2574.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang X, Wang YY, Jiang P, Ma JJ, Qu Z, Liu
HC, Wang SS and Wang YS: Clinical application of CyberKnife for
high-risk central nervous system tumors: A clinical trial report of
60 cases. Exp Ther Med. 3:105–108. 2012.PubMed/NCBI
|
|
11
|
Rutkowski MJ, Bloch O, Jian BJ, Chen C,
Sughrue ME, Tihan T, Barani IJ, Berger MS, McDermott MW and Parsa
AT: Management of recurrent intracranial hemangiopericytoma. J Clin
Neurosci. 18:1500–1504. 2011. View Article : Google Scholar
|
|
12
|
Cengiz M, Özyiğit G, Yazici G, Doğan A,
Yildiz F, Zorlu F, Gürkaynak M, Gullu IH, Hosal S and Akyol F:
Salvage reirradiaton with stereotactic body radiotherapy for
locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol
Phys. 81:104–109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim HM, Lim J, Yoon YD, Ahn JM, Kang JS,
Lee K, Park SK, Jeong YJ, Kim JM, Han G, Yang KH, Kim YJ, Kim Y and
Han SB: Anti-tumor activity of ex vivo expanded cytokine-induced
killer cells against human hepatocellular carcinoma. Int
Immunopharmacol. 7:1793–1801. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gütgemann S, Frank S, Strehl J and
Schmidt-Wolf IG: Cytokine-induced killer cells are type II natural
killer T cells. Ger Med Sci. 5:Doc072007.PubMed/NCBI
|
|
15
|
Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ,
Huang LX, Li YQ, Chen SP, Wu PH and Xia JC: Minimally invasive
treatment combined with cytokine-induced killer cells therapy lower
the short-term recurrence rates of hepatocellular carcinomas. J
Immunother. 31:63–71. 2008. View Article : Google Scholar
|
|
16
|
Olioso P, Giancola R, Di Riti M, Contento
A, Accorsi P and Iacone A: Immunotherapy with cytokine induced
killer cells in solid and hematopoietic tumours: a pilot clinical
trial. Hematol Oncol. 27:130–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maluf PJ, Michelin MA, Etchebehere RM,
Adad SJ and Murta EF: T lymphocytes (CD3) may participate in the
recurrence of cervical intraepithelial neoplasia grade III. Arch
Gynecol Obstet. 278:525–530. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Steffens HP, Kurz S, Holtappels R and
Reddehase MJ: Preemptive CD8 T-cell immunotherapy of acute
cytomegalovirus infection prevents lethal disease, limits the
burden of latent viral genomes, and reduces the risk of virus
recurrence. J Virol. 72:1797–1804. 1998.
|
|
19
|
Kägi D, Ledermann B, Bürki K, Seiler P,
Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM and Hengartner H:
Cytotoxicity mediated by T cells and natural killer cells is
greatly impaired in perforin-deficient mice. Nature. 369:31–37.
1994.PubMed/NCBI
|
